Study title: A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)
UMMC
PRINCIPAL INVESTIGATOR
Dr David Lee Dai Wee/ Toh Yok Yong
CONTACT
03-79492120
Hospital Pulau Pinang
PRINCIPAL INVESTIGATOR
Dr Tan Ai Lian
CONTACT
SC: Nurul Ainaa Jasmin Abu Hassan
+603 222 5766
Hospital Umum Sarawak
PRINCIPAL INVESTIGATOR
Dr Izzati Maharudding
CONTACT
SC: Anna Ting Huong Juan
+6082-276820
Hospital Sultan Ismail
PRINCIPAL INVESTIGATOR
Ooi Kai Yun
CONTACT
SC: Narmatha Gurumoorthy
+6012-7468 127
Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
NOOR ZAFIFAH BINTI ZAKARIA
CONTACT
SC: Faizah bt Mohd Hanapiah
+603-2615 5810
Institut Kanser Negara
PRINCIPAL INVESTIGATOR
Dr Suhana Yusak
CONTACT
SC: Nurul Afifah Rozkhaid
+603-8892 5555
An Open Label Trial of BI 765063 in Combination With BI 754091 (Ezabenlimab) Alone or With BI 836880, Chemotherapy, or Cetuximab, in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) or Hepatocellular Carcinoma (HCC) (BI1443-0002)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
Facebook
Sultan Ismail Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
DR LIM CHUN SEN
chunsen1@hotmail.com
CONTACT
General line: 07 – 356 5000
CRC: 07 – 356 5000 ext: 2408
Dr Munirah Admin Manager
drmunirah@hsi.gov.my (Email)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr Ho Gwo Fuang
fuang@ummc.edu.my
CONTACT
SC: Kimee 03-79492120 (Research Room)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
DR SUHANA BINTI YUSAK
suhanayusak@gmail.com
CONTACT
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)
A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
Dr Wong Yoke Fui
dryfwongnci.gov.my
CONTACT
SC: Abdul Hadi Hisham
abdul.hadi@clinicalresearch.my
Hospital Kuala Lumpur (HKL)
PRINCIPAL INVESTIGATOR
Dr Ibtisam Muhamad Nor
CONTACT
SC: Amirah binti Mohamed Tahir
amirah@clinicalresearch.my
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
FONG CHIN HENG
CONTACT
SC: Nur Adilah Abdul Aziz
General line: ’04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin, Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar
Admin Manager zarinacu@gmail.com (Email)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
WAN ZAMNIAH WAN ISHAK
CONTACT
SC: Suganiya
Contact no: 03-79492120
A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Standard of Care Therapeutic Agents in Participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (ORIGAMI-4)
Pantai Hospital Kuala Lumpur (PHKL)
PRINCIPAL INVESTIGATOR
Dr. Malwinder Singh Sandhu
CONTACT
General Line: 03 – 2296 0888
CRC: 03-22960888 Ext.1320, 1321, 1322
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
Dr David Lee Dai Wee
CONTACT
SC: Toh Yok Yong (03-79492120)